Team

Consultant-led, named, accountable

Pathology Nucleus is consultant-led. Every diagnostic output is signed off by a named, board-certified pathologist; clinical scientists support workflow and coordination.

About

Pathology Nucleus

Pathology Nucleus is a consultant-led group of UK and US board-certified pathologists delivering subspecialist diagnostic expertise, AI model validation and clinical research support to pharmaceutical, biotechnology and healthcare organisations.

We sit between raw clinical data and decision-making — providing the pathologist perspective that turns data collection into reliable diagnostics, reproducible biomarker frameworks and evidence that regulators trust.

ABPath certified & GMC registered

Board-certified by the American Board of Pathology and registered with the UK General Medical Council — meeting the credentialling standards of both US and UK regulatory environments.

Pharmaceutical and AI experience

Active collaborations with leading AI research organisations and global pharmaceutical companies — from LLM evaluation to companion diagnostic central review supporting EMA approval of immunotherapy programmes.

14 PubMed-indexed publications

Peer-reviewed research across haematopathology, dermatopathology and pathology methodology, including first-author work with the Bone Marrow Pathology Group.

Outputs aligned with EMA and FDA

Audit-ready documentation, locked queries and dual-review workflows structured for regulatory submission packages across European and US programmes.

Leadership

Founder & Medical Director

Dr Maximiliano Ramia de Cap
Dr Maximiliano Ramia de Cap
Founder & Medical Director

ABPath-certified consultant pathologist with subspecialty certification in Anatomic Pathology and Hematopathology, GMC-registered and currently practising at Imperial College Healthcare NHS Trust. Trained in the Harvard Medical System, with residency and fellowship at Beth Israel Deaconess Medical Center / Harvard Medical School.

Founder of Pathology Nucleus, leading collaborations with frontier AI organisations and global pharmaceutical sponsors across LLM evaluation, AI biomarker validation, and companion-diagnostic central review — including work supporting EMA approval of immunotherapy programmes.

Author of 14 PubMed-indexed publications spanning haematopathology, dermatopathology, pathology methodology and translational research.

Listed expert in the Health Data Forum Expert Hub, an independent body connecting organisations with specialists in health data, AI and digital health.

Max@PathologyNucleus.co.uk LinkedIn
Publications

Selected peer-reviewed publications

Fourteen PubMed-indexed publications spanning haematopathology, dermatopathology, pathology methodology and translational research, including first-author work with the Bone Marrow Pathology Group. Each title links to its PubMed record.

  1. Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma. Hum Pathol · 2026
  2. Hemophagocytic macrophages in the peripheral blood of a critically ill patient with COVID-19 and RSV infection. Am J Hematol · 2026
  3. Investigation of NPM1 mutation frequency in cutaneous blastic plasmacytoid dendritic cell neoplasms. Hum Pathol · 2025
  4. Myeloid sarcoma: an overview. Semin Diagn Pathol · 2023
  5. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group. Leuk Lymphoma · 2023
  6. NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype. Leuk Res · 2022
  7. Dogliotti and Phillips classifications are unsuitable for grading the histopathological findings of exogenous ochronosis. J Cutan Pathol · 2022
  8. Limitations of multivariate survival analysis. Mod Pathol · 2022
  9. Survival analysis and treatment effects in patients with endometrial cancer and POLE mutations. Cancer · 2021
  10. Exogenous ochronosis associated with dimethoxytolyl propylresorcinol (UP302). J Dermatol · 2021
  11. Multifocal papillary thyroid carcinoma. Am J Clin Pathol · 2021
  12. High prevalence of methotrexate use in patients with Epstein-Barr virus-positive mucocutaneous ulcer may cause confounding bias. Mod Pathol · 2021
  13. Impact of a modified HistoGel method for processing endocervical curettage specimens on diagnostic yield. Am J Clin Pathol · 2021
  14. Evaluation of the antioxidant capacity of a milk protein matrix in vitro and in vivo in women aged 50-70 years. Int J Food Sci Nutr · 2016
Network

The Pathology Nucleus Network

Pathology Nucleus draws on a network of 10+ board-certified consultant pathologists, allowing rapid assembly of subspecialist teams aligned to each project, spanning:

Teams are assembled per project based on subspecialty expertise and study requirements.

Subspecialty leads are assigned per engagement based on the scientific requirements of the project. Additional senior pathologists will be profiled here as they join the public roster.

Want to know which consultant
would lead your project?

Every engagement is led by a named pathologist with direct subspecialty expertise. Get in touch to discuss.

Get in touch